List of works - Oliver Hantschel

2016 International Symposium on Chemical Biology of the NCCR Chemical Biology Campus Biotech, Geneva 13-15.1.2016.

scientific article published in March 2016

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

scientific article published on 5 November 2009

A myristoyl/phosphotyrosine switch regulates c-Abl

scientific article published on March 2003

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain

scientific article

ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation

scientific article published on 10 January 2018

Alkaline phosphatase-fused repebody as a new format of immuno-reagent for an immunoassay

scientific article

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance ⬇️

scientific article published on February 1, 2012

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

scientific article published on 24 February 2016

Allosterische Kinaseinhibitoren

An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells

scientific article

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

scientific article published on 29 January 2012

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

scientific article

Bcr-Abl: one kinase, two isoforms, two diseases

scientific article published on 14 September 2017

BioSITe: A Method for Direct Detection and Quantitation of Site-Specific Biotinylation

scientific article published on 18 December 2017

Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms

scientific article published on 08 May 2020

CDK6 degradation hits Ph+ ALL hard

scientific article published on 01 April 2020

Cell biology: A key driver of therapeutic innovation ⬇️

scientific article published on November 12, 2012

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

scientific article

Charting the molecular network of the drug target Bcr-Abl

scientific article

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

scientific article published on 24 August 2007

Chronic myeloid leukemia – some topical issues

scientific article published on 10 May 2007

Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity

scientific article

Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics

scientific article

Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains

scientific article

Erratum: Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

scholarly article published in Leukemia

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

scientific article

HRD Motif as the Central Hub of the Signaling Network for Activation Loop Autophosphorylation in Abl Kinase

scientific article published on 28 September 2016

Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis

scientific article

Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases

scientific article

Kinase Regulation in Mycobacterium tuberculosis: Variations on a Theme.

scientific article

Kinase-templated abiotic reaction

scientific article published on 24 May 2017

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

scientific article published on 28 December 2012

Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis

scientific article published on September 2012

Molecular Simulations to Unravel the Allosteric Interplay between the SH2 Domain and A-loop Plasticity in Protein Kinases

article by Giuseppina La Sala et al published February 2017 in Biophysical Journal

Monobodies as enabling tools for structural and mechanistic biology

scientific article published on 01 February 2020

Monobodies as possible next-generation protein therapeutics - a perspective

scientific article published on 29 November 2017

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors

scientific article published on 30 August 2016

NMR Assignment Reveals an α-Helical Fold for the F-Actin Binding Domain of Human Bcr-Abl/c-Abl

NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins

scientific article published on 19 July 2013

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

scientific article published on 07 September 2011

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

scientific article published on 10 February 2016

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase

scientific article

Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate Specificity

scientific article published on 08 August 2019

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

scientific article published on January 2004

SY-20 The TBK-1 substrate DDX3X, a DEAD-box RNA helicase, provides innate immunity to listeria monocytogenes

Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies

scientific article

Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains

scientific article published on 17 August 2020

Single-molecule kinetic analysis of HP1-chromatin binding reveals a dynamic network of histone modification and DNA interactions.

scientific article published on 3 August 2017

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).

scientific article

Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase

scientific article published on 13 December 2017

Structural basis for the autoinhibition of c-Abl tyrosine kinase

scientific article (publication date: 21 March 2003)

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation

scientific article

Structure, regulation, signaling, and targeting of abl kinases in cancer ⬇️

scientific article published on May 1, 2012

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

scientific article

Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins

scientific article published on 03 May 2019

Targeting BCR-ABL and JAK2 in Ph+ ALL.

scientific article

Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable".

scientific article published in November 2011

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

scientific article

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

scholarly article

The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response

scientific article

The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility

scientific article published on 17 November 2014

The central domain of the matrix protein of HIV-1: influence on protein structure and virus infectivity.

scientific article

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.

scientific article published on 23 July 2008

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL ⬇️

scientific article published on September 21, 2012

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis

scientific article published on 08 April 2019

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

scientific article

Tuning SAS-6 architecture with monobodies impairs distinct steps of centriole assembly

scientific article published on 21 June 2021

Unexpected off-targets and paradoxical pathway activation by kinase inhibitors

scientific article published on 02 January 2015

Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function

scientific article published on 26 June 2017

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease

scientific article

γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia

scientific article published on 01 April 2019

List of works by Oliver Hantschel

2016 International Symposium on Chemical Biology of the NCCR Chemical Biology Campus Biotech, Geneva 13-15.1.2016.

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

A myristoyl/phosphotyrosine switch regulates c-Abl

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain

ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation

Alkaline phosphatase-fused repebody as a new format of immuno-reagent for an immunoassay

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance ⬇️

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

Allosterische Kinaseinhibitoren

An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Bcr-Abl: one kinase, two isoforms, two diseases

BioSITe: A Method for Direct Detection and Quantitation of Site-Specific Biotinylation

Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms

CDK6 degradation hits Ph+ ALL hard

Cell biology: A key driver of therapeutic innovation ⬇️

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

Charting the molecular network of the drug target Bcr-Abl

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Chronic myeloid leukemia – some topical issues

Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity

Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics

Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains

Erratum: Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

HRD Motif as the Central Hub of the Signaling Network for Activation Loop Autophosphorylation in Abl Kinase

Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis

Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases

Kinase Regulation in Mycobacterium tuberculosis: Variations on a Theme.

Kinase-templated abiotic reaction

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis

Molecular Simulations to Unravel the Allosteric Interplay between the SH2 Domain and A-loop Plasticity in Protein Kinases

Monobodies as enabling tools for structural and mechanistic biology

Monobodies as possible next-generation protein therapeutics - a perspective

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors

NMR Assignment Reveals an α-Helical Fold for the F-Actin Binding Domain of Human Bcr-Abl/c-Abl

NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase

Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate Specificity

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

SY-20 The TBK-1 substrate DDX3X, a DEAD-box RNA helicase, provides innate immunity to listeria monocytogenes

Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies

Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains

Single-molecule kinetic analysis of HP1-chromatin binding reveals a dynamic network of histone modification and DNA interactions.

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).

Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase

Structural basis for the autoinhibition of c-Abl tyrosine kinase

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation

Structure, regulation, signaling, and targeting of abl kinases in cancer ⬇️

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins

Targeting BCR-ABL and JAK2 in Ph+ ALL.

Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable".

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response

The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility

The central domain of the matrix protein of HIV-1: influence on protein structure and virus infectivity.

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL ⬇️

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Tuning SAS-6 architecture with monobodies impairs distinct steps of centriole assembly

Unexpected off-targets and paradoxical pathway activation by kinase inhibitors

Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease

γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia